The in vestigators are conducting a phase 1/2 study of fludarabine-based allo-HCT with the addition of carfilzomib in patients with hematologic malignancy. The investigators hypothesize that adding carfilzomib to standard fludarabine-based conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by decreasing severe GVHD, leading to overall improvement in transplant outcomes.
SparkCures ID | 610 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 55 Patients |
Treatments | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers